Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report, tel. 703.383.4903, Twitter@JimPharmSource, firstname.lastname@example.org(, http://www.pharmsource.com/.
Changes in company ownership shake up the CMO industry.
The R&D model is in transition and creating new demands on contract services providers.
Ongoing changes create new opportunities for CROs and CMOs.
Practicality of implementation should be a part of vision in the bio/pharmaceutical industry.
Are strategic partnerships in clinical research a model for CMC services?
Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.
An innovative approach to capacity management.
Is the contract-only CMO an endangered species?
Measuring the size of the market for contract manufacturing services requires a careful hand.